Table 1 Demographic and clinical characteristics of subjects with asthma and healthy controls
| Â | Healthy control | Asthma | ||
|---|---|---|---|---|
Mild | Moderate | Severe | ||
N | 35 | 22 | 32 | 22 |
Mean, age ±SD | 39 ± 12.86 | 39 ± 11.64 | 46 ± 16.1 | 52 ± 12.73 |
Gender, F|M | 15|20 | 13|9 | 19|13 | 16|6 |
Asthma duration, years (mean) | – | 18.33 | 16.03 | 21.48 |
Family history, n (%) | – | 15 (68.2) | 17 (53.1) | 15 (68.2) |
FEV% | – | 93 | 77.38 | 69.25 |
History of smoking, n (%) | 0 | 1 (4.5) | 1 (3.1) | 0 |
Current smoking, n (%) | 0 | 3 (13.6) | 3 (9.4) | 2 (9.1) |
SHS, n (%) | Â | 2 (9.1) | 2 (6.25) | 2 (9.1) |
Treatment | ||||
 ICS/LABA combined inhaler | ||||
  Budesonide/formoterol (160 µg/4.5 µg) | ||||
   n (%) | 0 | 0 | 23 (84.4) | 15 (77.3) |
   n/day |  |  | 2/day | 2/day |
  Fluticasone/Salmeterol (125 µg/25 µg) |  |  |  |  |
   n (%) | 0 | 0 | 9 (28.1) | 7 (31.8) |
  n/day |  |  | 2/day | 2/day |
 SABA | ||||
  Salbutamol (200 µg) | ||||
   n (%) | 0 | 1 (4.5) | 3 (9.4) | 22 (100) |
   n/day |  | 2/day | 4/day | 2/day |
   PRN |  | 21 (95.4) | 29 (90.6) | 0 |
 Tiotropium | ||||
  Spiriva (18 µg) | ||||
   n (%) | 0 | 0 | 0 | 15 (68.2) |
   n/day |  |  |  | 1/day |
 Montelukast | ||||
  Singulair (10 µg) | ||||
   n (%) | 0 | 0 | 12 (37.5) | 20 (90.9) |
   n/day, course |  |  | 1 course | 1/day |
 Anti-IgE | ||||
  Omalizumab (300 mg) | ||||
   n (%) | 0 | 0 | 0 | 19 (86.4) |
   n/month |  |  |  | 1/month |